Zacks: Analysts Expect Aclaris Therapeutics Inc (ACRS) Will Post Earnings of -$0.90 Per Share
Brokerages predict that Aclaris Therapeutics Inc (NASDAQ:ACRS) will report ($0.90) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Aclaris Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.88) and the lowest estimate coming in at ($0.92). Aclaris Therapeutics reported earnings per share of ($0.49) in the same quarter last year, which would suggest a negative year-over-year growth rate of 83.7%. The firm is scheduled to announce its next earnings report before the market opens on Monday, March 12th.
On average, analysts expect that Aclaris Therapeutics will report full-year earnings of ($2.59) per share for the current financial year, with EPS estimates ranging from ($2.65) to ($2.51). For the next year, analysts forecast that the company will post earnings of ($4.37) per share, with EPS estimates ranging from ($5.09) to ($3.62). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Aclaris Therapeutics.
A number of research analysts have issued reports on ACRS shares. BidaskClub lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, December 20th. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the stock a “buy” rating in a research report on Friday, December 15th. Zacks Investment Research upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 19th. Finally, Guggenheim started coverage on Aclaris Therapeutics in a research report on Thursday, February 8th. They set a “buy” rating and a $53.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $41.80.
Shares of Aclaris Therapeutics (NASDAQ:ACRS) traded up $0.91 during mid-day trading on Friday, reaching $20.45. The company’s stock had a trading volume of 268,594 shares, compared to its average volume of 340,170. Aclaris Therapeutics has a one year low of $18.46 and a one year high of $33.25. The firm has a market cap of $659.94 and a price-to-earnings ratio of -9.47.
TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Expect Aclaris Therapeutics Inc (ACRS) Will Post Earnings of -$0.90 Per Share” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/03/03/zacks-analysts-expect-aclaris-therapeutics-inc-acrs-will-post-earnings-of-0-90-per-share.html.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.